NCT03746275View on ClinicalTrials.gov

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid

CompletedOBSERVATIONAL
Enrollment

5,798

Participants

Timeline

Start Date

November 13, 2018

Primary Completion Date

June 8, 2021

Study Completion Date

July 13, 2021

Conditions
Atherosclerosis
Interventions
DRUG

Rivaroxaban (BAY59-7939, Xarelto)

2.5 mg twice daily

DRUG

Acetylsalicylic acid

75 - 100 mg once daily according to local label

Trial Locations (18)

Unknown

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Multiple facilities, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

Bayer

INDUSTRY